Use of Acrp30 globular head to promote increases in muscle mass and muscle differentiation
AssigneeSerono Genetics Institute S.A.
InventorsHarvey Lodish, Joachim Fruebis, Tsu-Shuen Tsao, Bernard Bihain
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of muscle research, in particular to the discovery of a compound effective for increasing muscle mass, muscle cell differentiation, and oxidation of free fatty acids in muscle, useful in methods of treating muscle-related diseases and disorders as well as for augmenting muscle mass in general. The muscle-related diseases or disorders envisaged to be treated by the methods of the invention include, but are not limited to, muscular dystrophy, and other conditions resulting in muscle atrophy or muscle wasting.
Claims36
A method of accelerating skeletal muscle cell differentiation, comprising contacting skeletal muscle cells in vitro with gOBG3 polypeptides consisting of:
- amino acids 101-244 of SEQ ID NO:
- 6, amino acids 108-244 of SEQ ID NO:
- 6, amino acids 104-247 of SEQ ID NOs:
- 2 or 4, or amino acids 111-247 of SEQ ID NOs:
- 2 or 4, or variants thereof comprising polyethylene glycol conjugated to gOBG3 polypeptides consisting of:
- amino acids 101-244 of SEQ ID NO:
- 6, amino acids 108-244 of SEQ ID NO:
- 6, amino acids 104-247 of SEQ ID NOs:
- 2 or 4, or amino acids 111-247 of SEQ ID NOs:
- 2 or 4, wherein said gOBG3 accelerates the differentiation of said cells.
A method of accelerating skeletal muscle cell realignment in relation to other skeletal muscle cells in vitro, comprising contacting skeletal muscle cells in vitro with gOBG3 polypeptides consisting of:
- amino acids 101-244 of SEQ ID NO:
- 6, amino acids 108-244 of SEQ ID NO:
- 6, amino acids 104-247 of SEQ ID NOs:
- 2or 4, or amino acids 111-247 of SEQ ID NOs:
- 2 or 4, or variants thereof comprising polyethylene glycol conjugated to gOBG3 polypeptides consisting of:
- amino acids 101-244 of SEQ ID NO:
- 6, amino acids 108-244 of SEQ ID NO:
- 6, amino acids 104-247 of SEQ ID NOs:
- 2 or 4, or amino acids 111-247 of SEQ ID NOs:
- 2 or 4 in an amount sufficient to accelerate the realignment of said skeletal muscle cells in relation to each other.
A method of treating skeletal muscle cell disorders selected from the group consisting of muscle-related recovery after injuries, muscle-related recovery after surgery, and muscle wasting in an individual, comprising diagnosing an individual as having a skeletal muscle cell disorder selected from the group consisting of muscle-related recovery after injuries, muscle-related recovery after surgery, and muscle wasting and administering to said diagnosed individual an amount of gOBG3 polypeptide consisting of:
- amino acids 101-244 of SEQ ID NO:
- 6, amino acids 108-244 of SEQ ID NO:
- 6, amino acids 104-247 of SEQ ID NOs:
- 2 or 4, amino acids 111-247 of SEQ ID NOs:
- 2 or 4, or variants thereof comprising polyethylene glycol conjugated to gOBG3 polypeptides consisting of:
- amino acids 101-244 of SEQ ID NO:
- 6, amino acids 108-244 of SEQ ID NO:
- 6, amino acids 104-247 of SEQ ID NOs:
- 2 or 4, or amino acids 111-247 of SEQ ID NOs:
- 2 or 4 sufficient to accelerate the reorganization and alignment of said cells in relation to each other and treat said disorder.
A method of treating skeletal muscle injury comprising selecting an individual having a skeletal muscle injury and administering to an individual in need thereof a therapeutically effective dose of gOBG3 polypeptide, said gOBG3 polypeptide consisting of:
- amino acids 101-244 of SEQ ID NO:
- 6, amino acids 108-244 of SEQ ID NO:
- 6, amino acids 104-247 of SEQ ID NOs:
- 2 or 4, or amino acids 111-247 of SEQ ID NOs:
- 2 or 4, or variants thereof comprising polyethyleneglycol conjugated to gOBG3 polypeptides consisting of:
- amino acids 101-244 of SEQ ID NO:
- 6, amino acids 108-244 of SEQ ID NO:
- 6, amino acids 104-247 of SEQ ID NOs:
- 2 or 4, or amino acids 111-247 of SEQ ID NOs:
- 2 or 4, wherein said therapeutically effective dose is sufficient for treating said skeletal muscle injury.
A method of treating a skeletal muscle disorder comprising diagnosing an individual as having a skeletal muscle disorder and administering to said diagnosed individual a therapeutically effective dose of gOBG3 polypeptide, said gOBG3 polypeptide consisting of:
- amino acids 101-244 of SEQ ID NO:
- 6, amino acids 108-244 of SEQ ID NO:
- 6, amino acids 104-247 of SEQ ID NOs:
- 2 or 4, amino acids 111-247 of SEQ ID NOs:
- 2 or 4, orvariants thereof comprising polyethylene glycol conjugated to gOBG3 polypeptides consisting of:
- amino acids 101-244 of SEQ ID NO:
- 6, amino acids 108-244 of SEQ ID NO:
- 6, amino acids 104-247 of SEQ ID NOs:
- 2 or 4, or amino acids 111-247 of SEQ ID NOs:
- 2 or 4, wherein said effective dose is sufficient for treating said skeletal muscle disorder.
Dependencies are inferred from the claim text.